BRPI0807480A2 - Ligando, imunoglobulina g, composição e proteína de fusão - Google Patents

Ligando, imunoglobulina g, composição e proteína de fusão

Info

Publication number
BRPI0807480A2
BRPI0807480A2 BRPI0807480-1A2A BRPI0807480A BRPI0807480A2 BR PI0807480 A2 BRPI0807480 A2 BR PI0807480A2 BR PI0807480 A BRPI0807480 A BR PI0807480A BR PI0807480 A2 BRPI0807480 A2 BR PI0807480A2
Authority
BR
Brazil
Prior art keywords
immunoglobulin
composition
fusion protein
fusion
protein
Prior art date
Application number
BRPI0807480-1A2A
Other languages
English (en)
Inventor
Ian M Tomlinson
Laurent S Jespers
Jasper Clube
Lucy J Holt
Oliver Schon
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of BRPI0807480A2 publication Critical patent/BRPI0807480A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0807480-1A2A 2007-02-08 2008-02-08 Ligando, imunoglobulina g, composição e proteína de fusão BRPI0807480A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/704,832 US9321832B2 (en) 2002-06-28 2007-02-08 Ligand
PCT/GB2008/000453 WO2008096158A2 (en) 2007-02-08 2008-02-08 Antibody single variable domains against serum albumin

Publications (1)

Publication Number Publication Date
BRPI0807480A2 true BRPI0807480A2 (pt) 2014-05-06

Family

ID=39518148

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0807480-1A2A BRPI0807480A2 (pt) 2007-02-08 2008-02-08 Ligando, imunoglobulina g, composição e proteína de fusão

Country Status (16)

Country Link
US (2) US9321832B2 (pt)
EP (4) EP2559704A1 (pt)
JP (2) JP5562650B2 (pt)
KR (2) KR20090114445A (pt)
CN (1) CN101965364A (pt)
AR (1) AR065260A1 (pt)
AU (1) AU2008212682B2 (pt)
BR (1) BRPI0807480A2 (pt)
CA (1) CA2677069A1 (pt)
CL (1) CL2008000423A1 (pt)
EA (1) EA020464B9 (pt)
ES (2) ES2629333T3 (pt)
MX (1) MX2009008490A (pt)
SG (1) SG185869A1 (pt)
TW (1) TW200848427A (pt)
WO (1) WO2008096158A2 (pt)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009231439A1 (en) * 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
UY31861A (es) 2008-06-03 2010-01-05 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
WO2010006060A2 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
US9327022B2 (en) 2008-10-14 2016-05-03 National Research Council Of Canada BSA-specific antibodies
ES2688621T3 (es) 2008-12-05 2018-11-05 Glaxo Group Limited Métodos para seleccionar polipéptidos resistentes a proteasa
EA028178B1 (ru) 2009-02-19 2017-10-31 Глэксо Груп Лимитед Улучшенные связывающие сывороточный альбумин варианты
WO2010094722A2 (en) * 2009-02-19 2010-08-26 Glaxo Group Limited Improved anti-serum albumin binding variants
SG173173A1 (en) * 2009-02-19 2011-08-29 Glaxo Group Ltd Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
JP2012521971A (ja) * 2009-03-27 2012-09-20 グラクソ グループ リミテッド 薬物融合体および複合体
EP2421611A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited Fgfr1c antibody combinations
WO2011008814A2 (en) 2009-07-14 2011-01-20 Immune Tolerance Institute, Inc., A California Not-For-Profit Corporation Multiplexed measurement of exogenous and endogenous dna
CA2768460A1 (en) 2009-07-16 2011-01-20 Glaxo Group Limited Antagonists, uses & methods for partially inhibiting tnfr1
SG177601A1 (en) 2009-07-16 2012-02-28 Glaxo Group Ltd Improved anti-serum albumin binding single variable domains
EA026097B1 (ru) 2009-07-29 2017-03-31 Глаксо Груп Лимитед Однодоменные антитела против рецептора tgf-бета ii типа
NZ598929A (en) * 2009-09-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
CN102666586A (zh) 2009-09-30 2012-09-12 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物
TW201119676A (en) * 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AR078763A1 (es) 2009-10-27 2011-11-30 Glaxo Group Ltd Polipeptidos anti factor de necrosis tumoral 1 (anti-tnfr1) estables, dominios variables de anticuerpos y antagonistas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CA2786660A1 (en) 2010-01-14 2011-07-21 Glaxo Group Limited Liver targeting molecules
EP2560992A2 (en) * 2010-04-21 2013-02-27 Glaxo Group Limited Binding domains
KR20130109977A (ko) 2010-05-20 2013-10-08 글락소 그룹 리미티드 개선된 항-혈청 알부민 결합 변이체
WO2011146891A2 (en) * 2010-05-21 2011-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
CA2800173C (en) 2010-05-21 2019-05-14 Ulrik Nielsen Bi-specific fusion proteins
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
US9012609B2 (en) * 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
SG188204A1 (en) 2010-08-20 2013-04-30 Glaxo Group Ltd Improved anti-serum albumin binding variants
AU2011293253B2 (en) 2010-08-26 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
JP6105479B2 (ja) 2010-11-26 2017-03-29 モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ 血清アルブミンに結合する設計リピートタンパク質
JP2014501515A (ja) 2010-12-01 2014-01-23 グラクソ グループ リミテッド 改良された抗血清アルブミン結合単一可変ドメイン
EP2661449B1 (en) 2011-01-06 2017-03-22 Glaxo Group Limited Ligands that bind tgf-beta receptor ii
EP2670778A1 (en) 2011-02-02 2013-12-11 Glaxo Group Limited Novel antigen binding proteins
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
EP2726506A1 (en) 2011-05-27 2014-05-07 Dutalys Removal of monomeric targets
CN103930445B (zh) 2011-05-27 2021-03-09 豪夫迈·罗氏有限公司 双靶向
EP3466972A1 (en) 2011-06-23 2019-04-10 Ablynx NV Serum albumin binding proteins
EP3363812A1 (en) * 2011-06-23 2018-08-22 Ablynx NV Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
HUE031828T2 (en) 2011-06-23 2017-08-28 Ablynx Nv Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
EP2776466B1 (en) 2011-11-11 2017-08-23 UCB Biopharma SPRL Albumin binding antibodies and binding fragments thereof
CA2861610A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
CN102661932B (zh) * 2012-04-17 2014-07-23 王利兵 一种基于表面等离子共振技术的种质资源中特定dna序列鉴定方法
EP4151658A1 (en) 2012-05-07 2023-03-22 Elasmogen Limited Single domain binding molecule
EP2888279A1 (en) 2012-08-22 2015-07-01 Glaxo Group Limited Anti lrp6 antibodies
NZ707641A (en) 2012-11-01 2016-09-30 Abbvie Inc Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
KR101763352B1 (ko) 2013-03-15 2017-07-31 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 항­ｌａｇ­3 결합 단백질
TW201512219A (zh) 2013-03-15 2015-04-01 Abbvie Inc 針對ＩＬ－１β及／或ＩＬ－１７之雙特異性結合蛋白
JP6591964B2 (ja) 2013-04-23 2019-10-16 ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン Ｉｃｏｓｌへの治療上の標的特異的ｖｎａｒドメインの単離
AU2014312456B2 (en) * 2013-08-30 2017-07-06 Aprilbio Co., Ltd An anti serum albumin Fab-effector moiety fusion construct, and the preparing method thereof
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
KR102472862B1 (ko) * 2014-03-20 2022-12-05 브리스톨-마이어스 스큅 컴퍼니 혈청 알부민-결합 피브로넥틴 유형 iii 도메인
MX2016014926A (es) 2014-05-16 2017-05-09 Ablynx Nv Dominios variables de inmunoglobulina mejorados.
TW201629215A (zh) * 2014-09-30 2016-08-16 拜耳保健有限責任公司 使用凝血酶之組成物及治療方法
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
US20180057551A1 (en) * 2015-02-20 2018-03-01 Affibody Ab Alzheimer abeta peptide binding polypeptide
CN107454904A (zh) 2015-04-02 2017-12-08 分子组合公司 对血清白蛋白具有结合特异性的经设计的锚蛋白重复结构域
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
ES2842306T3 (es) 2015-09-02 2021-07-13 Immutep Sas Anticuerpos anti LAG-3
ES2781207T3 (es) 2015-09-23 2020-08-31 Bristol Myers Squibb Co Dominios de fibronectina de tipo iii de unión a seroalbúmina con velocidad de disociación rápida
CN115960249A (zh) 2015-10-02 2023-04-14 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
NO2768984T3 (pt) 2015-11-12 2018-06-09
CN108290943A (zh) 2015-11-13 2018-07-17 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白可变结构域
GEP20217220B (en) 2015-11-18 2021-02-10 Merck Sharp & Dohme Pd1 and/or lag3 binders
GEP20207174B (en) 2015-11-18 2020-11-10 Merck Sharp & Dohme Ctla4 binders
CN109071639B (zh) 2015-11-18 2022-07-08 默沙东公司 Pd1/ctla4结合剂
WO2017085172A2 (en) 2015-11-18 2017-05-26 Ablynx Nv Improved serum albumin binders
US20190338013A1 (en) 2016-02-26 2019-11-07 Imunexus Pty Ltd Multi-Specific Molecules
US20190119387A1 (en) 2016-04-05 2019-04-25 Glaxosmithkline Intellectual Property Development Limited Inhibition of tgfbeta in immunotherapy
EP3448873B1 (en) * 2016-04-25 2023-12-20 Idea Orchard, LLC Engineered fha domains
MA45051A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant la relaxine
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
SG11201810327XA (en) 2016-05-20 2018-12-28 Harpoon Therapeutics Inc Single domain serum albumin binding protein
BR112018073761A2 (pt) 2016-05-20 2019-02-26 Harpoon Therapeutics, Inc. proteínas de ligação ao cd3 de fragmento variável de cadeia única
CA3044659A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
US10844134B2 (en) 2016-11-23 2020-11-24 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
BR112019011189A2 (pt) * 2016-12-07 2019-10-08 Ablynx Nv domínios variáveis únicos de imunoglobulina que se ligam à albumina sérica melhorada
IL305912A (en) 2017-01-17 2023-11-01 Ablynx Nv Improved serum albumin binding agents
WO2018134235A1 (en) * 2017-01-17 2018-07-26 Ablynx Nv Improved serum albumin binders
CN118557758A (zh) 2017-02-10 2024-08-30 瑞泽恩制药公司 用于免疫-pet成像的放射性标记的抗-lag3抗体
CN110461871B (zh) 2017-02-16 2024-04-26 索纳特生物疗法公司 白蛋白结合结构域融合蛋白
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
JP6886854B2 (ja) * 2017-04-13 2021-06-16 シスメックス株式会社 被検物質の情報取得方法
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
CA3063359A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
EP3634997A1 (en) * 2017-06-05 2020-04-15 Numab Therapeutics AG Novel anti-hsa antibodies
CA3070253A1 (en) * 2017-07-19 2019-01-24 Vib Vzw Serum albumin binding agents
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
CN111194323B (zh) 2017-10-10 2024-07-09 努玛治疗有限公司 多特异性抗体
PT3694529T (pt) 2017-10-13 2024-09-20 Harpoon Therapeutics Inc Proteínas triespecíficas e métodos de utilização
JP7066837B2 (ja) 2017-10-13 2022-05-13 ハープーン セラピューティクス，インク． Ｂ細胞成熟抗原結合タンパク質
CA3102823A1 (en) 2018-06-22 2019-12-26 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
AU2019328313A1 (en) 2018-08-30 2021-02-25 Immunitybio, Inc. Single-chain chimeric polypeptides and uses thereof
US11730762B2 (en) 2018-08-30 2023-08-22 HCW Biologics, Inc. Methods for stimulating proliferation or differentiation of an immune cell with a multi-chain chimeric polypeptide
AU2019328290B2 (en) 2018-08-30 2024-10-10 Immunitybio, Inc. Multi-chain chimeric polypeptides and uses thereof
WO2020069028A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
GB201818460D0 (en) * 2018-11-13 2018-12-26 Crescendo Biologics Ltd Single domain antibodies that bind human serum albumin
CN112830967B (zh) * 2019-01-10 2022-06-24 瑞阳(苏州)生物科技有限公司 抗hsa单域抗体及其融合蛋白的亲和层析纯化方法
EP3987010A1 (en) * 2019-06-21 2022-04-27 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
EP3816185A1 (en) 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
CA3169231A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
BR112022016550A2 (pt) 2020-02-21 2022-11-16 Harpoon Therapeutics Inc Proteínas de ligação a flt3 e métodos de uso
EP4133084A1 (en) 2020-04-09 2023-02-15 Autolus Limited Polypeptide
GB202007441D0 (en) 2020-05-19 2020-07-01 Autolus Ltd Polypeptide
EP3915580A1 (en) 2020-05-29 2021-12-01 Numab Therapeutics AG Multispecific antibody
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
EP3988568A1 (en) 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
IL303295A (en) 2020-12-07 2023-07-01 UCB Biopharma SRL Multispecific antibodies and antibody combinations
MX2023009022A (es) 2021-02-02 2023-10-23 Numab Therapeutics AG Anticuerpos multiespecificos con especificidad para ror1 y cd3.
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES
WO2024084203A1 (en) * 2022-10-18 2024-04-25 Isogenica Limited Single domain antibodies binding to albumin
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor

Family Cites Families (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US700598A (en) 1901-03-21 1902-05-20 Le Carbone Sa Primary battery.
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
EP0467416A1 (en) 1983-09-01 1992-01-22 Hybritech Incorporated Antibody compositions of therapeutic agents having an extended serum half-life
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
SU1441787A1 (ru) 1987-04-29 1990-09-23 Институт Белка Ан Ссср Способ получени пептидов и белков в бесклеточной системе трансл ции
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ES2056108T3 (es) 1987-07-07 1994-10-01 Hybrisens Ltd Empleo de interacciones anticuerpo/antigeno para proteger o modular la actividad biologica.
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5225540A (en) 1988-04-26 1993-07-06 Du Pont Merck Pharmaceutical Company Monoclonal antibodies to tissue plasminogen activator (t-pa) which prolong its functional half-life
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
AU649217B2 (en) 1988-11-18 1994-05-19 Regents Of The University Of California, The Method for site-specifically incorporating unnatural amino acids into proteins
SU1705302A1 (ru) 1988-12-22 1992-01-15 Институт Белка Ан Ссср Способ препаративной экспрессии генов в бесклеточной системе сопр женной транскрипции/трансл ции
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
WO1991002076A1 (fr) 1989-07-31 1991-02-21 Institut Belka Akademii Nauk Sssr Procede d'obtention de polypeptides dans un systeme exempt de cellules
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6448380B2 (en) 1989-08-07 2002-09-10 Peptech Limited Tumor necrosis factor antibodies
EP0486526B2 (en) 1989-08-07 2001-03-07 Peptech Limited Tumour necrosis factor binding ligands
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
DK0494955T3 (da) 1989-10-05 1998-10-26 Optein Inc Cellefri syntese og isolering af hidtil ukendte gener og polypeptider
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5459061A (en) 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ATE160818T1 (de) 1990-06-01 1997-12-15 Chiron Corp Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9016299D0 (en) 1990-07-25 1990-09-12 Brien Caroline J O Binding substances
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
AU8498091A (en) 1990-08-02 1992-03-02 Regents Of The University Of Colorado, The Systematic polypeptide evolution by reverse translation
WO1992005258A1 (en) 1990-09-20 1992-04-02 La Trobe University Gene encoding barley enzyme
US5726152A (en) 1990-09-21 1998-03-10 Merck & Co., Inc. Vascular endothelial cell growth factor II
CA2104698A1 (en) 1991-02-21 1992-08-22 John J. Toole Aptamers specific for biomolecules and methods of making
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
JPH06508985A (ja) 1991-02-27 1994-10-13 クリエイティブ　バイオモレキュルズ　インコーポレイテッド 富セリンペプチドリンカー
CZ282603B6 (cs) 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanizované a chimerické monoklonální protilátky
OA10149A (en) 1991-03-29 1996-12-18 Genentech Inc Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
JPH06509563A (ja) 1991-07-05 1994-10-27 セラゲン・インコーポレイテッド 炎症性関節炎の治療用の表皮細胞成長因子受容体を標的とする分子
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
WO1995011922A1 (en) 1993-10-29 1995-05-04 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
IL112372A (en) 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
GB9410533D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
ATE208633T1 (de) 1994-09-16 2001-11-15 Merck Patent Gmbh Immunokonjugate
US5573957A (en) 1994-09-28 1996-11-12 Spectral Diagnostics, Inc. Monoclonal antibody to human cardiac myoglobin
US5712381A (en) 1994-10-19 1998-01-27 Genetics Institute, Inc. MADD, a TNF receptor death domain ligand protein
US5928939A (en) 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
DE69606592T2 (de) 1995-07-11 2000-09-21 E.I. Du Pont De Nemours And Co., Wilmington Tintensortiment und Verfahren zum Vermindern des Ausblutens in Druckelementen
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US5664034A (en) 1996-05-21 1997-09-02 Lucent Technologies Inc. Lightwave communication monitoring switch
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6013780A (en) 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
DK1717322T3 (da) 1997-01-17 2012-10-22 Codexis Mayflower Holdings Llc Udvikling af hele celler og organismer ved rekursiv sekvensrekombination
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US20030165467A1 (en) 1997-01-21 2003-09-04 Technion Research & Development Co., Ltd. Angiogenic factor and use thereof in treating cardiovascular disease
DE69835143T2 (de) 1997-01-21 2007-06-06 The General Hospital Corp., Boston Selektion von proteinen mittels rns-protein fusionen
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6485942B1 (en) 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
AUPO561697A0 (en) 1997-03-13 1997-04-10 Crc For Cardiac Technology Haemocompatible surfaces
ATE418608T1 (de) 1997-03-18 2009-01-15 Novozymes As Methode zur herstellung einer bibliothek mittels dna-shuffling
BR9808368A (pt) 1997-03-18 2000-05-23 Novo Nordisk As Processos para a construção de uma biblioteca de polinucleotideos homólogos recombinados, para a identificação um polipeptìdeo de interesse, e, para a produção de um polipeptìdeo de interesse.
US5948653A (en) 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
US6153410A (en) 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
EP0979102A4 (en) 1997-04-30 2005-11-23 Enzon Inc DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
AU8800598A (en) 1997-06-20 1999-01-04 Innogenetics N.V. B7-binding molecules for treating immune diseases
EP1496120B1 (en) 1997-07-07 2007-03-28 Medical Research Council In vitro sorting method
WO1999005163A1 (en) 1997-07-24 1999-02-04 Medical Research Council Refolding method using a foldase and a chaperone
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
AU2152299A (en) 1997-10-27 1999-05-24 Unilever Plc Multivalent antigen-binding proteins
WO1999021979A1 (en) 1997-10-28 1999-05-06 Maxygen, Inc. Human papillomavirus vectors
EP1030861A4 (en) 1997-10-31 2001-09-05 Maxygen Inc MODIFICATION OF VIRAL TROPISM AND THE DIVERSITY OF HOST SPECIES BY RECOMBINATION OF THE VIRAL GENOME
EP1036198B1 (en) 1997-12-08 2012-09-26 California Institute Of Technology Method for creating polynucleotide and polypeptide sequences
US6777534B1 (en) 1997-12-09 2004-08-17 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
DE69922159T2 (de) 1998-01-23 2005-12-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Mehrzweck-antikörperderivate
EP1053343A2 (en) 1998-02-11 2000-11-22 Maxygen, Inc. Targeting of genetic vaccine vectors
EP1054973A1 (en) 1998-02-11 2000-11-29 Maxygen, Inc. Antigen library immunization
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US20020192211A1 (en) 1998-03-17 2002-12-19 Hudziak Robert M. Method of treating tumor cells by inhibiting growth factor receptor function
US20030224001A1 (en) 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US20030175271A1 (en) 1998-05-20 2003-09-18 Kyowa Hakko Kogyo Co., Ltd. VEGF activity inhibitor
CN1308683A (zh) 1998-06-29 2001-08-15 菲洛斯公司 用于产生高多样性文库的方法
US7264801B2 (en) 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
FR2782323B1 (fr) 1998-08-12 2002-01-11 Proteus Procede de production in vitro de sequences polynucleotidiques recombinees, banques de sequences et sequences ainsi obtenues
SG113454A1 (en) 1998-09-24 2005-08-29 Upjohn Co Alzheimer's disease secretase
JP2002537758A (ja) 1998-09-29 2002-11-12 マキシジェン， インコーポレイテッド コドン変更された遺伝子のシャッフリング
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
EP1002861A1 (en) 1998-10-26 2000-05-24 Unilever Plc Antigen-binding proteins comprising a linker which confers restricted conformational flexibility
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
DE69935248T2 (de) 1998-12-02 2007-11-08 Adnexus Therapeutics, Inc., Waltham Dna-protein fusionen sowie anwendungen derselben
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP2016953A3 (en) 1998-12-22 2009-04-15 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
GB9900298D0 (en) 1999-01-07 1999-02-24 Medical Res Council Optical sorting method
EP1151409A1 (en) 1999-01-18 2001-11-07 Maxygen, Inc. Methods of populating data stuctures for use in evolutionary simulations
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
AU3210100A (en) 1999-01-19 2000-08-01 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
WO2000060070A1 (en) 1999-04-01 2000-10-12 Innogenetics N.V. A polypeptide structure for use as a scaffold
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
CA2372053C (en) 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
JP2003502024A (ja) 1999-05-14 2003-01-21 メディカル リサーチ カウンシル タンパク質骨格および単量体ポリペプチドを多量体化するためのその使用
EE200100603A (et) 1999-05-14 2003-02-17 Imclone Systems Incorporated Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega
US7049410B2 (en) 1999-05-14 2006-05-23 Majumdar Adhip P N Antibodies to a novel EGF-receptor related protein (ERRP)
US6475796B1 (en) 1999-05-20 2002-11-05 Scios, Inc. Vascular endothelial growth factor variants
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
PT1240337E (pt) 1999-12-24 2007-01-31 Genentech Inc Métodos e composições para prolongar as meias-vidas de eliminação de compostos bioactivos
CA2399388A1 (en) 2000-02-11 2001-08-16 Michael J. Lenardo Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
JP4981229B2 (ja) 2000-02-25 2012-07-18 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ハイブリッド血管内皮成長因子ＤＮＡｓおよびタンパク質に関与する物質および方法
US20050019826A1 (en) 2000-03-31 2005-01-27 Roselyne Tournaire Peptides blocking vascular endothelial growth factor(vegf)-mediated angiogenesis, polynucleotides encoding said pepetides and methods of use thereof
EP1272647B1 (en) 2000-04-11 2014-11-12 Genentech, Inc. Multivalent antibodies and uses therefor
WO2001089549A2 (en) 2000-05-22 2001-11-29 Hyseq, Inc. Therapeutic uses of il-1 receptor antagonist
US20020103345A1 (en) 2000-05-24 2002-08-01 Zhenping Zhu Bispecific immunoglobulin-like antigen binding proteins and method of production
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
EP1297142B1 (en) 2000-06-29 2009-01-14 Abbott Laboratories Dual specificity antibodies and methods of making and using
DE10038624C2 (de) 2000-08-03 2002-11-21 Broekelmann Aluminium F W Wärmeübertragungsrohr mit gedrallten Innenrippen
EP1343820A4 (en) 2000-10-13 2005-09-14 Uab Research Foundation ANTI-EPIDERMIC GROWTH FACTOR RECEPTOR SINGLE CHAIN ANTIBODY
KR20080085082A (ko) 2000-12-07 2008-09-22 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 융합 단백질
EP1345967B1 (en) 2000-12-22 2011-08-10 Grad, Carole, Legal representative of Kaplan, Howard Phage display libraries of human v h fragments
US7054297B1 (en) 2000-12-28 2006-05-30 Cisco Technology, Inc. Distribution of packets to high data rate communications devices using multicast protocols
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2002072141A2 (en) 2001-03-09 2002-09-19 William Herman Targeted ligands
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
ATE472609T1 (de) 2001-04-26 2010-07-15 Amgen Mountain View Inc Kombinatorische bibliotheken von monomerdomänen
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
CN1507355A (zh) 2001-05-08 2004-06-23 Ĭ��ר�����޹�˾ 使用抗egfr抗体和抗激素剂的联合疗法
CN1966525A (zh) 2001-06-13 2007-05-23 根马布股份公司 表皮生长因子受体(egfr)的人单克隆抗体
US20050271663A1 (en) 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20040248196A1 (en) 2001-08-03 2004-12-09 Adams Timothy Edward Methods of screening based on the egf receptor crystal structure
AU2002332054B2 (en) 2001-09-24 2007-11-08 Imperial Innovations Limited Modification of feeding behavior
IL161418A0 (en) 2001-10-15 2004-09-27 Immunomedics Inc Direct targeting binding proteins
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1456651B1 (en) 2001-11-30 2008-05-07 National Research Council Of Canada Self-assembly molecules
DE10163459A1 (de) 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
WO2003057235A2 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Modification of feeding behavior
AU2003209446B2 (en) 2002-03-01 2008-09-25 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
EP1576172A2 (en) 2002-06-21 2005-09-21 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
NZ538569A (en) 2002-09-06 2009-02-28 Amgen Inc Therapeutic human anti-IL-1R1 monoclonal antibody
TW200501960A (en) 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
JP5179702B2 (ja) 2002-10-10 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 受容体Ｅｒｂ−Ｂ１に対する医薬組成物
EP2336179A1 (en) 2002-11-08 2011-06-22 Ablynx N.V. Stabilized single domain antibodies
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
EP2390270A1 (en) 2003-01-10 2011-11-30 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
CN1829806A (zh) 2003-02-01 2006-09-06 唐纳士公司 产生高亲和力抗体的方法
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
WO2004101790A1 (en) 2003-05-14 2004-11-25 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
CA2519875C (en) 2003-06-06 2014-01-14 Regeneron Pharmaceuticals, Inc. Method of tumor regression with vegf inhibitors
KR101531400B1 (ko) 2003-06-27 2015-06-26 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도
PT1639011E (pt) 2003-06-30 2009-01-20 Domantis Ltd Anticorpos (dab) de domínio único peguilados
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050196340A1 (en) 2003-08-06 2005-09-08 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy
CA2534898A1 (en) 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
EP1675878A2 (en) 2003-10-24 2006-07-05 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
EP2251357A1 (en) 2003-11-07 2010-11-17 Ablynx N.V. Camelidae single domain antibodies VHH directed against epidermal growth factor receptor and uses therefor
US20050226863A1 (en) 2003-11-20 2005-10-13 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
DK1709081T3 (da) 2004-01-16 2011-06-06 Regeneron Pharma Fusionspolypeptider, der kan aktivere receptorer
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
MXPA06014031A (es) 2004-06-01 2007-10-08 Domantis Ltd Anticuerpos de fusion biespecificos con vida media de serica mejorada.
ES2372503T3 (es) 2004-07-06 2012-01-20 Bioren, Inc. Mutagénesis revisada para desarrollar polipéptidos alterados con propiedades potenciadas.
US7180370B2 (en) 2004-09-01 2007-02-20 Micron Technology, Inc. CMOS amplifiers with frequency compensating capacitors
KR20070084069A (ko) 2004-10-08 2007-08-24 도만티스 리미티드 Ｔｎｆｒ1에 대한 단일 도메인 항체 및 이의 사용 방법
CN101111522A (zh) 2004-12-02 2008-01-23 杜门蒂斯有限公司 由于和功能域抗体缀合而具有提高的血清半衰期的plad功能域肽
WO2006059108A2 (en) * 2004-12-02 2006-06-08 Domantis Limited ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
BRPI0518761A2 (pt) * 2004-12-02 2008-12-09 Domantis Ltd fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
MX342271B (es) 2005-05-18 2016-09-21 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
TW200804425A (en) 2005-12-06 2008-01-16 Domantis Ltd Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof

Also Published As

Publication number Publication date
TW200848427A (en) 2008-12-16
EP2559702A1 (en) 2013-02-20
ES2629353T3 (es) 2017-08-08
EP2559703A1 (en) 2013-02-20
AU2008212682B2 (en) 2013-09-26
JP2014193869A (ja) 2014-10-09
EA020464B1 (ru) 2014-11-28
EP2559702B1 (en) 2017-04-19
AR065260A1 (es) 2009-05-27
WO2008096158A8 (en) 2009-10-15
EA200900955A1 (ru) 2010-04-30
KR20150014995A (ko) 2015-02-09
CA2677069A1 (en) 2008-08-14
EP2139918B1 (en) 2017-04-19
JP5562650B2 (ja) 2014-07-30
CL2008000423A1 (es) 2008-10-24
WO2008096158A2 (en) 2008-08-14
WO2008096158A3 (en) 2008-12-18
KR20090114445A (ko) 2009-11-03
US20090259026A1 (en) 2009-10-15
US20170145080A1 (en) 2017-05-25
EP2559704A1 (en) 2013-02-20
EP2139918A2 (en) 2010-01-06
MX2009008490A (es) 2010-01-15
JP2010518062A (ja) 2010-05-27
ES2629333T3 (es) 2017-08-08
EA020464B9 (ru) 2015-10-30
SG185869A1 (en) 2012-12-28
AU2008212682A1 (en) 2008-08-14
CN101965364A (zh) 2011-02-02
US9321832B2 (en) 2016-04-26

Similar Documents

Publication Publication Date Title
BRPI0807480A2 (pt) Ligando, imunoglobulina g, composição e proteína de fusão
HK1219490A1 (zh) 免疫球蛋白融合蛋白
BRPI0918947A2 (pt) proteína de fusão de anticorpo
BRPI0716744A2 (pt) proteínas de fusão de albumina
ATE524493T1 (de) Exendin-fusionsproteine
BRPI0813452A2 (pt) protéinas de fusão rage.
BRPI0906722A2 (pt) Métodos e composições usando polipeptídeos de fusão klotho-fgf
IL196889A0 (en) Albumin-insulin fusion proteins
BRPI0819210A2 (pt) Anticorpos de proteína g anti-rsv
IL204839A0 (en) Albumin fusion proteins
DK1999154T3 (da) Fremstillede heterodimere proteindomæner
DK3118220T3 (da) Protein
BRPI0820342A2 (pt) Modulação de tráfego de proteína
IL212538A0 (en) Albumin fusion proteins
DE602006008266D1 (de) Klemm- und Gelenkelement
IL218296A0 (en) Obpgplys/endolysin polypeptides, fusion proteins and compositions compriisng the same and uses thereof
NO20071302L (no) Bindingdomene fusjonsproteiner
IL204111A (en) Preparations of notch fusion proteins are individualized and used
EP1934372A4 (en) SSB-POLYMERASE HYBRID PROTEINS
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
BRPI0814971A2 (pt) Proteína
DOP2011000347A (es) Proteina de enlace de il-13
BRPI0814127A2 (pt) Polipeptídeos imunegênicos e anticorpos monoclonais
DK2219675T3 (da) Formuleringer for taci-immunglobulin-fusionsproteiner
ES2569360T8 (es) Proteínas de fusión de ácaros

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]